Human disease
osteosarcoma
Mondo defines it as: “A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1441 | Osteosarcoma | The group's name | 4 | Human disease |
37.5
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
Open Targets links none of these groups' human genes to this disease.
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Leucovorin | None of these genes | Approved |
| Levoleucovorin | None of these genes | Approved |
| Mifamurtide Acid | None of these genes | Approved |
| Bleomycin | None of these genes | Phase 3 |
| Cisplatin | None of these genes | Phase 3 |
| Cyclophosphamide Anhydrous | None of these genes | Phase 3 |
| Dactinomycin | None of these genes | Phase 3 |
| Dexrazoxane | None of these genes | Phase 3 |
| Dinutuximab Beta | None of these genes | Phase 3 |
| Docetaxel Anhydrous | None of these genes | Phase 3 |
| Doxorubicin | None of these genes | Phase 3 |
| Etoposide | None of these genes | Phase 3 |
| Filgrastim | None of these genes | Phase 3 |
| Gemcitabine | None of these genes | Phase 3 |
| Ifosfamide | None of these genes | Phase 3 |
| Methotrexate | None of these genes | Phase 3 |
| Peginterferon Alfa-2b | None of these genes | Phase 3 |
| Zoledronic Acid Anhydrous | None of these genes | Phase 3 |
| Cabozantinib | None of these genes | Phase 2/3 |
| Lobaplatin | None of these genes | Phase 2/3 |
| Rivoceranib | None of these genes | Phase 2/3 |
| Abemaciclib | None of these genes | Phase 2 |
| Aldesleukin | None of these genes | Phase 2 |
| Alisertib | None of these genes | Phase 2 |
| Atezolizumab | None of these genes | Phase 2 |
| Avelumab | None of these genes | Phase 2 |
| Bevacizumab | None of these genes | Phase 2 |
| Bio-11006 | None of these genes | Phase 2 |
| Camrelizumab | None of these genes | Phase 2 |
| Carboplatin | None of these genes | Phase 2 |
| Celecoxib | None of these genes | Phase 2 |
| Ceralasertib | None of these genes | Phase 2 |
| Cixutumumab | None of these genes | Phase 2 |
| Denosumab | None of these genes | Phase 2 |
| Dinutuximab | None of these genes | Phase 2 |
| Disulfiram | None of these genes | Phase 2 |
| Durvalumab | None of these genes | Phase 2 |
| Eflornithine | None of these genes | Phase 2 |
| Endostatin, N-Terminal-Mggshhhhh | None of these genes | Phase 2 |
| Envafolimab | None of these genes | Phase 2 |
| Eribulin | None of these genes | Phase 2 |
| Everolimus | None of these genes | Phase 2 |
| Fludarabine | None of these genes | Phase 2 |
| Fruquintinib | None of these genes | Phase 2 |
| Gefitinib | None of these genes | Phase 2 |
| Glembatumumab Vedotin | None of these genes | Phase 2 |
| Glucarpidase | None of these genes | Phase 2 |
| Imatinib | None of these genes | Phase 2 |
| Interferon Alfa | None of these genes | Phase 2 |
| Ipilimumab | None of these genes | Phase 2 |
| Ixabepilone | None of these genes | Phase 2 |
| Lenvatinib | None of these genes | Phase 2 |
| Lifileucel | None of these genes | Phase 2 |
| Metformin | None of these genes | Phase 2 |
| Molgramostim | None of these genes | Phase 2 |
| Naxitamab | None of these genes | Phase 2 |
| Nivolumab | None of these genes | Phase 2 |
| Olaparib | None of these genes | Phase 2 |
| Oleclumab | None of these genes | Phase 2 |
| Paclitaxel | None of these genes | Phase 2 |
| Palbociclib | None of these genes | Phase 2 |
| Panobinostat | None of these genes | Phase 2 |
| Pazopanib | None of these genes | Phase 2 |
| Pegargiminase | None of these genes | Phase 2 |
| Pelareorep | None of these genes | Phase 2 |
| Pembrolizumab | None of these genes | Phase 2 |
| Pemetrexed | None of these genes | Phase 2 |
| Penpulimab | None of these genes | Phase 2 |
| Regorafenib | None of these genes | Phase 2 |
| Regramostim | None of these genes | Phase 2 |
| Ridaforolimus | None of these genes | Phase 2 |
| Robatumumab | None of these genes | Phase 2 |
| Saracatinib | None of these genes | Phase 2 |
| Sargramostim | None of these genes | Phase 2 |
| Sirolimus | None of these genes | Phase 2 |
| Sorafenib | None of these genes | Phase 2 |
| Sunitinib | None of these genes | Phase 2 |
| Surufatinib | None of these genes | Phase 2 |
| Temozolomide | None of these genes | Phase 2 |
| Temsirolimus | None of these genes | Phase 2 |
| Teprotumumab | None of these genes | Phase 2 |
| Thiotepa | None of these genes | Phase 2 |
| Tideglusib | None of these genes | Phase 2 |
| Topotecan | None of these genes | Phase 2 |
| Trabectedin | None of these genes | Phase 2 |
| Trametinib | None of these genes | Phase 2 |
| Trastuzumab | None of these genes | Phase 2 |
| Tremelimumab | None of these genes | Phase 2 |
| Trilaciclib | None of these genes | Phase 2 |
| Trimetrexate | None of these genes | Phase 2 |
| Tucidinostat | None of these genes | Phase 2 |
| Vinblastine | None of these genes | Phase 2 |
| Vincristine | None of these genes | Phase 2 |
| Vinorelbine | None of these genes | Phase 2 |
| Zanzalintinib | None of these genes | Phase 2 |
| Anti-Gd2 Monoclonal Antibody 3f8 | None of these genes | Phase 1/2 |
| Dacarbazine | None of these genes | Phase 1/2 |
| Endostatin | None of these genes | Phase 1/2 |
| Epirubicin | None of these genes | Phase 1/2 |
| Famitinib | None of these genes | Phase 1/2 |
| Figitumumab | None of these genes | Phase 1/2 |
| Hydroxychloroquine | None of these genes | Phase 1/2 |
| Irinotecan | None of these genes | Phase 1/2 |
| Natalizumab | None of these genes | Phase 1/2 |
| Pepinemab | None of these genes | Phase 1/2 |
| Radium Ra 223 Dichloride | None of these genes | Phase 1/2 |
| Socazolimab | None of these genes | Phase 1/2 |
| Tegavivint | None of these genes | Phase 1/2 |
| Trastuzumab Deruxtecan | None of these genes | Phase 1/2 |
| Troculeucel | None of these genes | Phase 1/2 |
| Vactosertib | None of these genes | Phase 1/2 |
| 2-Mercaptoethanesulfonic Acid | None of these genes | Phase 1 |
| Azacitidine | None of these genes | Phase 1 |
| Azenosertib | None of these genes | Phase 1 |
| Catequentinib | None of these genes | Phase 1 |
| Decitabine | None of these genes | Phase 1 |
| Dotmp Sm-153 | None of these genes | Phase 1 |
| Emd-273063 | None of these genes | Phase 1 |
| Enoblituzumab | None of these genes | Phase 1 |
| Ferumoxytol | None of these genes | Phase 1 |
| Interferon Gamma-1b | None of these genes | Phase 1 |
| Interleukin-12 Human Recombinant | None of these genes | Phase 1 |
| Interleukin 15, Recombinant Non-Glycosylated | None of these genes | Phase 1 |
| Lexatumumab | None of these genes | Phase 1 |
| Losartan | None of these genes | Phase 1 |
| Magrolimab | None of these genes | Phase 1 |
| Pegfilgrastim | None of these genes | Phase 1 |
| Pexastimogene Devacirepvec | None of these genes | Phase 1 |
| Rimiducid | None of these genes | Phase 1 |
| Selinexor | None of these genes | Phase 1 |
| Simvastatin | None of these genes | Phase 1 |
| Somatostatin | None of these genes | Phase 1 |
| Tamoxifen | None of these genes | Phase 1 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.